Skip to Main Content

Paper Details

First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.
Eur Urol
24
2022
Author NameAffiliation
Timothy M KuzelRush Medical College
  • 1 - 1

Datasets

Release 1.2